Company news

Cellectar Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

March 8, 2020

Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study

February 18, 2020

Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

January 8, 2020

Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

January 6, 2020

Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)

January 5, 2020

Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

December 15, 2019

Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference

December 1, 2019

Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

November 11, 2019

Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

October 16, 2019

Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

October 7, 2019

Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

September 23, 2019

Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

September 15, 2019

Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

September 9, 2019

← Newer news releases

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 25 decks. Every deck is listed under its year.